Last reviewed · How we verify

Tritanrix-HepB/Hib™ + OPV vaccine — Competitive Intelligence Brief

Tritanrix-HepB/Hib™ + OPV vaccine (Tritanrix-HepB/Hib™ + OPV vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

phase 3 vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Tritanrix-HepB/Hib™ + OPV vaccine (Tritanrix-HepB/Hib™ + OPV vaccine) — Sanofi Pasteur, a Sanofi Company. Tritanrix-HepB/Hib™ + OPV vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tritanrix-HepB/Hib™ + OPV vaccine TARGET Tritanrix-HepB/Hib™ + OPV vaccine Sanofi Pasteur, a Sanofi Company phase 3 vaccine
Comirnaty BNT162b2 (tozinameran) Pfizer Inc. marketed vaccine SARS-CoV-2 virus 2021-08-23
Prevnar 20 pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
Sabin IPV Sabin IPV Centers for Disease Control and Prevention, China marketed inactivated viral vaccine poliovirus serotypes 1, 2, and 3
Healive+Healive Healive+Healive Sinovac Biotech Co., Ltd marketed Combination vaccine Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
Meningococcal A (control) Meningococcal A (control) International Vaccine Institute marketed polysaccharide vaccine Neisseria meningitidis serogroup A capsular polysaccharide
Intranasal Influenza Live Attenuated Vaccine Intranasal Influenza Live Attenuated Vaccine Jiangsu Province Centers for Disease Control and Prevention marketed Live attenuated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (vaccine class)

  1. Pfizer · 20 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
  3. GlaxoSmithKline · 12 drugs in this class
  4. Merck Sharp & Dohme LLC · 12 drugs in this class
  5. Centers for Disease Control and Prevention · 9 drugs in this class
  6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
  7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
  8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
  9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
  10. Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tritanrix-HepB/Hib™ + OPV vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/tritanrix-hepb-hib-opv-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: